Silexion Therapeutics Corp. (SLXN) has announced a 1-for-15 reverse share split of its ordinary shares, effective after market close on July 28, 2025.
Trading on a split-adjusted basis will begin on July 29 under the same Nasdaq ticker "SLXN," with a new CUSIP number assigned to the post-split shares.
As part of the reverse split, every fifteen existing ordinary shares will automatically combine into one, increasing the par value from $0.0009 to $0.0135 per share. No fractional shares will be issued; shareholders entitled to a fraction will receive one whole share. Adjustments for shareholders will occur automatically, whether shares are held directly or via a broker.
Chairman and CEO Ilan Hadar said the reverse split underscores Silexion's commitment to maintaining its Nasdaq listing, improving capital market positioning, and supporting its long-term growth strategy. He emphasized the move follows preclinical progress with RNAi candidate SIL-204 and expanded efforts targeting KRAS-driven cancers.
The reverse split aims to bring the company's stock price into compliance with Nasdaq's minimum bid requirement under Rule 5550(a)(2), facilitating continued access to equity markets and supporting the company's broader strategic and financing initiatives.
Wednesday, SLXN closed at $0.695, down 10.40%, and edged slightly lower in after-hours trading to $0.69, a 0.72% decline on the NasdaqGM.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.